Dr. Zimran Discusses Gaucher Disease Biomarkers

Video

Dr. Ari Zimran, from Shaare Zedek Medical Center, Jerusalem, Discusses Biomarkers in Gaucher Disease

Ari Zimran, MD, Shaare Zedek Medical Center in Jerusalem, Israel, discusses the use of biomarkers in Gaucher disease, which help physicians monitor the progression of the disease.

A typical parameter for identifying Gaucher disease is a blood test. A typical panel looks for levels of angiotensin converting enzyme, chitotriosidase, and tartrate resistant acid phosphatase. Patients that are stable will also have stable biomarkers whereas patients who are deteriorating will have an elevated expression of the markers. An increase in the biomarkers can precede the deterioration of the patient, which can lead the physician to start therapy.

The expression of biomarkers should go down in patients who are receiving treatment and those that go up during treatment can hint to the possibility of an impending complication. When that is the case physician should see the patient more frequently or increase the treatment dose.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Annie Im, MD, FASCO
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology